Formulation Development and Evaluation of Tablet in Tablet Dosage Form for Quick and Protracted Relief in Gastritis and Allied Gastric Disorders

Abstract

Tablets are the most widely prescribed dosage form amidst all available alternatives because of its precise dosing, convenience to use, and low cost (Bandelin FJ, 1989). The Tablet in Tablet technique is an innovative and pragmatic approach, where a tablet is compressed with a core tablet in the center. This technique is recognized by different terms namely, OSDrC (One step dry coating), press coated tablet, compression coated tablet, single/bilayer core containing tablets, compression embedding technique, and dry coating. This technique may serves as coating over the core tablet, with numerous advantages over conventional pan coating technique. The key benefit of this technology is, exclusion of water/solvent during coating, thus there isn t any core softening or undesirable chemical reaction because of water/solvent penetration into the core tablet (Gunsel WC and Dusel RG, 1989). The core tablet is coated by compression in single step thus eliminating various time consuming steps (diverse alternative steps of coating and drying) followed during conventional pan coating procedure (Gunsel WC and Dusel RG, 1989). There are numerous formulations developed bagging patents using Tablet in Tablet technology moreover the Tablet in Tablet technology is conventionally used to manufacture sustained release, control release, and delayed release tablet formulation (Gunsel WC and Dusel RG, 1989). The present research was an attempt to develop a unique modified immediate release formulation in which both API s (in core and in outer tablet) work in synergy and produce meaningful pharmacological outcome in gastritis and allied gastric disorders besides improving patient compliance. The root cause of many gastric complications is hyperchlorhydria; which manifests acute to chronic medical complications viz. dyspepsia, heartburn, indigestion to hypergastrinemic syndromes like gastric ulcers, gastro esophageal reflux disease (GERD), Zollinger-Ellison syndrome. The core tablet comprises Esomeprazole; it is the drug of choice amongst PPI and available therapeutic alternatives for overcoming complication associated with hyperchlorhydria. It is generally formulated with sodium bicarbonate to provide momentary elevation in pH to prevent drug degradation at lower pH environment (Benetti C et al., 2016). newline